Endothelial cell tetrahydrobiopterin deficiency attenuates LPS-induced vascular dysfunction and hypotension☆

Surawee Chuaiaphichai a,b, Anna Starr c, Manasi Nandi c, Keith M. Channon a,b, Eileen McNeill a,b,c,*

a British Heart Foundation Centre of Research Excellence, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK
b Wellcome Trust Centre for Human Genetics, University of Oxford, UK
c Pharmacology and Therapeutics Group, Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King’s College London, UK

1. Introduction

Endotoxaemia is a leading cause of morbidity and mortality, characterised by systemic inflammation, decreased peripheral vascular resistance, microvascular leak and decreased cardiac output leading to refractory hypotension [24]. High levels of nitric oxide (NO) production by inducible nitric oxide synthase (iNOS), which can be induced by lipopolysaccharide (LPS), are believed to be a key mediator of these phenomena [21]. The synthesis of NO by all NOS isoforms requires the cofactor tetrahydrobiopterin (BH4). Biosynthesis of BH4 is catalysed by GTP cyclohydrolase I (GTPCH), a rate limiting enzyme for de novo BH4 biosynthesis, which is encoded by Gch1. Increased circulating plasma biopterins and nitrite/nitrate have been reported in both animal and human septic shock [3,10,14,15,29,31].

We have previously shown that Gch1 expression is a key determinant of BH4 bioavailability, NOS regulation and NO generation in the vasculature of healthy mice [7,9,30]. In the vascular system, pro-inflammatory stimuli have been shown to increase the synthesis of BH4 levels by up-regulating Gch1 mRNA and expression, that accompanies up-regulation of iNOS mRNA and protein in the endothelium and vascular smooth muscle [16,22,23]. Increased vascular iNOS-derived NO generation reduces vasoconstrictor response and causes hypotension which underlies pathophysiology of endotoxaemia and septic shock. The relevant contribution of endothelial NOS production to vascular dysregulation following systemic endotxin exposure is unknown. Previous works have also demonstrated the important role of endothelial NOS (eNOS) in the pathogenesis of LPS-induced endotoxaemia and septic shock that eNOS activity is the key determinant of iNOS expression and activity in murine model of septic shock [8,32]. Indeed, mice with global eNOS deficiency are protected against LPS-induced vascular dysfunction and hypotension due to loss of iNOS expression and activity [8,32].
2.2. Gch1 conditional endothelial knockout mice fed normal chow and water ad libitum. Procedures Act, 1986). Mice were housed in ventilated cages with a using Cre/loxP strategy. Exons 2 and 3 of Gch1 are deleted in endothelial cell-speciﬁc vs. systemic effects of NOS are important.

We have utilised a mouse model with endothelial cell-speciﬁc deletion of BH4 biosynthesis to investigate the importance of endothelial cell-derived NO production in the vascular and hemodynamic responses to LPS-induced endotoxaemia.

2. Material and methods

2.1. Animals

All animal studies were conducted with ethical approval from the Local Ethical Review Committee and in accordance with the UK Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986). Mice were housed in ventilated cages with a 12-hour light/dark cycle and controlled temperature (20–22 °C), and fed normal chow and water ad libitum.

2.2. Gch1 conditional endothelial knockout mice

We have generated a Gch1 conditional knockout (ﬂexed) allele using Cre/loxP strategy. Exons 2 and 3 of Gch1, encoding for the active site of GTPCH I, were flanked by two loxP sites in a targeting construct that was used to produce Gch1fl/ﬂ mice after homologous recombination in embryonic stem cells. Pups carrying the Gch1 ﬂexed allele were then back-crossed for 8 generations to the C57Bl/6j line. Once back-crossed the resultant Gch1fl/ﬂ animals were bred with Tie2cre transgenic mice to produce Gch1fl/ﬂTie2cre mice where Gch1 is deleted in endothelial cells, generating a novel mouse model of endothelial cell-speciﬁc BH4 deﬁciency mouse [7]. The Tie2cre transgene is active in the female germline, as such only male animals are used to establish breeding pairs to maintain conditional expression. Mice were genotyped according to the published protocol [7].

2.3. Non-invasive blood pressure measurement using tail-cuff method

Blood pressure in conscious wild-type and Gch1fl/ﬂTie2cre mice was measured using the Visitech BP-2000 tail-cuff plethysmography system. Experiments were performed between the hours of 8:00 am and 12:00 pm. Twenty readings were taken per mouse of which the ﬁrst 5 readings were discarded. The remaining 15 readings were used to calculate the mean systolic blood pressure and heart rate in each mouse. Following 5 days of training, basal blood pressure and heart rate were recorded for 3 consecutive days.

2.4. Administration of LPS

LPS (1 mg/kg body weight; Sigma-Aldrich, Gillingham, UK) or sterile saline was administered in male wild-type and Gch1fl/ﬂTie2cre mice (16–22 week-old) via intraperitoneal (i.p.) route. Mice were injected between 8:00 and 9:00 am for all studies to avoid diurnal variation in the response to LPS. Mice were monitored throughout the study for adverse effects. LPS administration is expected to cause a systemic inﬂammation and hypotension, which may lead to hypothermia. To counteract this, mice were maintained in a heated recovery cage and were given a subcutaneous injection of saline in accordance with local ethical requirements. 24-hour post injection, mice were culled and tissues were collected. The dose of LPS used was not lethal in any experimental animals.

2.5. Determination of tissue tetrahydrobiopterin levels

BH4 and oxidised biopotersins (BH2 and biopoterin) were determined by high-performance liquid chromatography (HPLC) followed by electrochemical and ﬂuorescence detection, respectively, following an established protocol [4]. Briefly, either a small piece of tissue (approximately 20 mg) or a whole aorta was resuspended in ice-cold resuspension buffer (50 mM phosphate-buffered saline, 1 mM dithioerythritol, 1 mM EDTA, pH 7.4), and either homogenised (for tissues) or subjected to three freeze–thaw cycles (for aortas). After centrifugation at 13,200 rpm for 10 min at 4 °C, supernatant was removed and ice-cold acid precipitation buffer (1 M phosphoric acid, 2 M trichloroacetic acid, 1 mM dithioerythritol) was added. Following centrifugation at 13,200 rpm for 10 min at 4 °C, the supernatant was removed and injected onto the HPLC system. Quantification of BH4 and oxidised biopotersins was obtained by comparison with external standards and normalised to protein concentration, determined by the BCA protein assay.

2.6. Isometric tension vasomotor studies

Vasomotor function was analysed using isometric tension studies in a wire myograph (Multi-Myograph 610M, Danish Myo Technology, Denmark). Briefly, mice were culled by overdose of inhaled isoflurane and vascular rings were isolated from the thoracic aorta or mesenteric arcades. The aortic rings or 2nd mesenteric arteries (2 mm) were mounted on a wire myograph containing 5 ml of Krebs–Henseleit buffer (KHb [in mmol/l]: NaCl 120, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, glucose 5.5) at 37 °C, gassed with 95% O2/5% CO2. After allowing vessels to equilibrate for 30 min, the optimal tension was set (equivalent to 100 mm Hg). The vessel viability was tested using 60 mM KCl. Concentration–response contraction curves were established using cumulative half-log concentrations of phenylephrine and U46619 in the presence or absence of 100 μM of non-selective NOS inhibitor, L-NAME. Acetylcholine was used to stimulate endothelium-dependent vasodilations in increasing cumulative concentrations. Responses were expressed as a percentage of the pre-constricted tension. The NO donor sodium nitroprusside (SNP) was used to test endothelium-independent smooth muscle relaxation in the presence of 100 μM L-NAME. All pharmacological drugs were pre-incubated at least 20 min before the dose–response curves were determined. All drugs used were purchased from Sigma Chemical Company.

2.7. NOx determination

Lung homogenates and plasma were deproteinated in acid precipitation buffer (1 M phosphoric acid, 2 M trichloroacetic acid), and the nitrite and nitrate content was quantiﬁed using a CLD88 NO analyser (Ecophysics).

2.8. Western blot analysis

Western blots were performed with anti- GTPCH (a gift from S. Gross, Cornell University New York), anti- iNOS (Abcam) and anti-eNOS (BD Bioscience) antibodies in vascular tissues from wild-type and Gch1fl/ﬂTie2cre mice, using standard protocols.

2.9. Quantification real-time RT-PCR

RNA were reserve transcribed using Superscript II (Life Technologies) according to standard protocols. 5 ng RNA equivalent CDNA was used to perform real-time PCR using pre-designed TaqMan gene
expression assays (Life Technologies) using a BioRad CFX1000. Gene expression levels of mouse Gch1, Nos3 and Nos2 were normalised to the housekeeping gene GAPDH using the Delta Ct method.

2.10. Statistical analysis

Data are expressed as mean ± standard error of the means and analysed using GraphPad Prism version 5.0 (San Diego, USA). Comparisons between WT and Gch1fl/fl Tie2cre were made by unpaired Student’s t test. Concentration–response curves were compared by two-way analysis of variance for repeated measurements followed by the Bonferroni post-hoc test. A P-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Endothelial cell-targeted Gch1 deletion and BH4 deficiency attenuates lipopolysaccharide-induced hypotension

We generated matched litters of Gch1fl/Tie2cre and Gch1fl/fl mice by crossing male Gch1fl/Tie2cre with female Gch1fl/fl mice (hereafter referred as wild-type). Body weights between the groups were similar. Blood pressure recordings were performed at 6 h and 24 h post LPS administration (1 mg/kg i.p.). As was the case with our previous study [7], baseline systolic blood pressure was significantly increased in Gch1fl/fl/Tie2cre mice compared to wild-type littermates (105.8 ± 2.2 mm Hg versus 98.8 ± 2.0 mm Hg; P < 0.05). Six-hours after LPS injection, systolic blood pressures were significantly decreased in both wild-type (80.1 ± 3.2 mm Hg; P < 0.01) and Gch1fl/fl/Tie2cre mice (95.3 ± 2.9 mm Hg; P < 0.05) (Fig. 1A), but with a significantly greater reduction in blood pressure in wild-type mice compared to Gch1fl/fl/Tie2cre mice (change in blood pressure, −20.8 ± 3.7 mm Hg in wild-type versus −7.9 ± 4.2 mm Hg in Gch1fl/fl/Tie2cre mice; P < 0.05) (Fig. 1C). 24 h after LPS injection, Gch1fl/fl/Tie2cre mice remained significantly less hypotensive than wild-type mice (change in BP from baseline, −24.3 ± 3.0 mm Hg in wild-type versus −12.5 ± 2.8 mm Hg in Gch1fl/fl/Tie2cre mice; P < 0.05). Baseline heart rate was similar between wild-type and Gch1fl/fl/Tie2cre mice. Administration of LPS significantly reduced the heart rate of both genotypes at 6 h after injection (from 680 ± 12 bpm to 603 ± 17 bpm in wild-type mice; from 694 ± 10 bpm to 598 ± 15 bpm in Gch1fl/fl/Tie2cre mice) and 24-hour post injection (592 ± 22 bpm in wild-type mice; 572 ±

Fig. 1. Effect of LPS on hemodynamic parameters in Gch1fl/fl/Tie2cre mice. Mice from both genotypes either received a single dose of 1 mg/kg lipopolysaccharide (LPS) or saline control i.p. and then underwent non-invasive tail-cuff recordings. A) Systolic blood pressure (mm Hg), and B) heart rate (beat per minute) were monitored at baseline, 6 and 24 h following injection. The C) change in blood pressure and D) heart rate from baseline at the two timepoints was calculated (*P < 0.05, **P < 0.01 comparing genotypes, #P < 0.05, ##P < 0.01 comparing treatment; n = 6 animals per group).
20 bpm in Gch1fl/flTie2cre mice) (Fig. 1B and D), but this was not significantly different between genotypes. As expected, saline treatment had no significant effect on systolic blood pressures or heart rates in either genotype (data not shown).

3.2. Increased vascular GTPCH and BH4 levels are attenuated in Gch1fl/flTie2cre mice following LPS in vivo

Gene expression and western blot analysis of aortic extracts confirmed that basal vascular Gch1 expression and GTPCH protein were significantly reduced in aortas from saline-treated Gch1fl/flTie2cre mice when compared with saline-treated wild-type controls (Fig. 2A, B, and C). Following LPS treatment, vascular Gch1 expression and GTPCH protein were increased in both wild-type and Gch1fl/flTie2cre mice, but remained significantly higher in wild-type mice (Fig. 2A, B, and C). This was accompanied by a significant decrease in vascular BH4 and total bipterin levels in saline-treated Gch1fl/flTie2cre mice compared to saline-treated wild-type mice (P < 0.05) (Fig. 2D). LPS treatment also increased vascular BH4 and total bipterin levels. However, the increase in vascular BH4 following LPS was significantly attenuated when endothelial BH4 production was absent in keeping with GTPCH protein expression (P < 0.01) (Fig. 2D). Furthermore, vascular BH4 levels were significantly decreased by ≈70% in endothelial-denuded aortas from wild-type mice following LPS treatment such that vascular BH4 was no longer different between LPS treated wild-type and LPS treated Gch1fl/flTie2cre mice. Removal of the endothelium has no significant effect on vascular BH4 levels in LPS treated Gch1fl/flTie2cre mice, suggesting a complete excision of Gch1 gene with Tie2 in endothelial cells in this model. This finding indicates significant upregulation of vascular GTPCH protein and thus BH4 biosynthesis in the endothelium following LPS in vivo (Fig. 2E).

3.3. LPS treatment has no effect on vascular reactivity in aortas in both wild-type and endothelial cell BH4 deficient mice

We next determined the effect of LPS on vascular reactivity in conduit vessels. As was the case with our previous study [7], we found that vasoconstriction in response to phenylephrine was significantly enhanced in Gch1fl/flTie2cre aortas compared to wild-type controls (P < 0.05). This difference was normalised in the presence of L-NAME (Fig. 3A and B). Endothelium-dependent vasodilatation was minimally enhanced in Gch1fl/flTie2cre aortas compared to wild-type controls (Fig. 3C). In the presence of H2O2 scavenger, catalase-polyethylene glycol (PEG-catalase), endothelium-dependent vasodilatations were significantly inhibited in Gch1fl/flTie2cre aortas but unchanged in wild-type aortas (Fig. 3D). There was no difference in endothelium-independent vasodilatation to SNP between the genotypes (Fig. 3E).

Despite an increase in aortic GTPCH and BH4 levels following in vivo LPS treatment, aortic vasoconstriction and vasodilatation were unaffected by LPS treatment (Fig. 3A, B, C, D and E). Gene expression and western blot analysis demonstrated that LPS treatment had no significant effect on either aortic eNOS or iNOS expression or protein in either

---

**Fig. 2.** Vascular GTPCH and BH4 levels in aortas. A) Representative immunoblots showing aortic GTP cyclohydrolase (GTPCH) protein in wild-type and Gch1fl/flTie2cre mice either treated with saline control or 1 mg/kg lipopolysaccharide (LPS) for 24 h, with corresponding quantitative data in B), measured as percentage band density of β-tubulin (a loading control) (*P < 0.05; comparing genotypes; **P < 0.01; comparing treatment; n = 6 aortas per group). C) Quantitative real-time PCR was used to quantify Gch1 gene expression in aortic extracts (*P < 0.05; comparing genotypes; **P < 0.01; comparing treatment; n = 4 aortas per group). D) Aortic BH4 and total bipterin levels, measured by HPLC, were significantly reduced in aortas from saline-treated Gch1fl/flTie2cre mice compared to saline-treated wild-type littermates. Following 1 mg/kg LPS treatment for 24 h, aortic BH4 and total bipterin levels were significantly elevated in both genotypes, but the difference still maintained (*P < 0.05; **P < 0.001 comparing genotypes; ***P < 0.001 comparing treatment; n = 6 to 8 aortas per group). E) Vascular BH4 in endothelium-denuded aortas from wild-type and Gch1fl/flTie2cre mice following LPS in vivo (**P < 0.001 comparing genotypes; ***P < 0.001 comparing treatment; n = 4 to 5 aortas per group).
Fig. 3. Effect of LPS on vascular reactivity in isolated aortas in vivo. Vasconstriction in response to phenylephrine A) alone or B) in the presence of non-selective nitric oxide synthase inhibitor, L-NAME (100 mM) in aortic rings from wild-type and Gch1fl/fl Tie2cre either treated with saline control or 1 mg/kg lipopolysaccharide (LPS) for 24 h (*P < 0.05; comparing genotype; n = 6 to 8 animals per group). Endothelium-dependent vasodilatation to acetylcholine C) alone or D) in the presence of catalase-polyethylene glycol (PEG-catalase; 400 units/ml) (*P < 0.05, **P < 0.01; comparing genotype; n = 4 to 6 animals per group). E) Endothelium-independent vasodilatation to sodium nitroprusside (SNP). F) Representative immunoblots showing endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) protein in aortas from wild-type and Gch1fl/fl Tie2cre treated with either saline control or LPS in vivo with corresponding quantitative data in G and H), measured as percentage band density of β-tubulin (a loading control) (n = 6 aortas per group). I and J) Quantitative real-time PCR was used to quantify iNOS and eNOS gene expression in aortic extracts from wild-type and Gch1fl/fl Tie2cre either treated with saline control or LPS in vivo (n = 4 aortas per group).
wild-type or Gch1<sup>fl/fl</sup>Tie2cre mice (Fig. 3F, G, H, I and J). This finding suggests that upregulation of vascular GTPCH and BH4 levels alone, without alteration of NOS expression, has no significant effect on vasomotor function in conduit vessels following LPS treatment in vivo.

3.4. Increased vascular GTPCH, BH4 levels, and NO generation are attenuated in tissues from Gch1<sup>fl/fl</sup>Tie2cre mice following LPS in vivo

To determine whether the dose of LPS given was sufficient to cause systemic alteration of Gch1 and NOS biology we analysed further endothelial cell-rich tissues, such as lung and heart. As previously observed BH4 and total bipterin levels were significantly reduced in saline treated Gch1<sup>fl/fl</sup>Tie2cre mice when compared with saline treated wild-type mice (Figs. 4A and B). Following LPS treatment, BH4 and total bipterin levels were significantly increased in both lung and heart tissues from wild-type mice and slightly increased but not statistically significant in Gch1<sup>fl/fl</sup>Tie2cre mice (Fig. 4A and B). However this regulation of BH4 levels by LPS treatment was not seen in all tissues, as the liver showed no significant difference in BH4 levels between saline treated mice and LPS treated mice in either wild-type or Gch1<sup>fl/fl</sup>Tie2cre mice (Fig. 4C). However, dihydrobiopterin (BH2), which lacks NOS cofactor activity, levels were significantly increased in the liver from both wild-type and Gch1<sup>fl/fl</sup>Tie2cre mice following LPS, such that the BH4/ (BH2 + bipterin) ratio was significantly reduced in both wild-type and Gch1<sup>fl/fl</sup>Tie2cre mice (Fig. S1). Furthermore, western blot analysis of lung extracts confirmed that LPS treatment caused a significant

---

**Fig. 4.** BH4, GTPCH protein, and NO production in endotoxaemic mice. The levels of BH4 and total bipterin, measured by HPLC, in A) lung, B) heart, C) liver, and D) plasma from wild-type and Gch1<sup>fl/fl</sup>Tie2cre either treated with saline control or 1 mg/kg LPS for 24 h (*p < 0.05; **p < 0.01; ***p < 0.001 comparing genotypes, #p < 0.05, ##p < 0.01, ###p < 0.001 comparing treatment; n = 4 to 6 animals per group). E) Representative immunoblots showing GTP cyclohydrolase (GTPCH) protein in lung homogenates from wild-type and Gch1<sup>fl/fl</sup>Tie2cre either treated with saline control or LPS. Total nitrite and nitrate content, measured by NO analyser, in F) lung homogenates and G) plasma following saline control or LPS treatment in vivo (*p < 0.05; comparing genotypes, #p < 0.05, comparing treatment; n = 4 to 6 animals per group).
increase in GTPCH protein in wild-type but unchanged in Gch1/fl/Tie2cre mice (Fig. 4E). This was accompanied by a significant increase in nitrite/nitrate content in lung homogenates from LPS treated wild-type mice, which was not detected in LPS treated Gch1/fl/Tie2cre mice, indicating that NOS activity is altered in the Gch1/fl/Tie2cre mice (Fig. 4F).

In plasma, there was no detectable difference in basal BH4 and total biopterin levels between saline-treated GCH1/fl/Tie2cre and saline-treated wild-type mice (Fig. 4D). Following LPS treatment, plasma BH4 levels were unchanged, but plasma total biopterin levels were significantly increased in both wild-type and Gch1/fl/Tie2cre mice, indicating an increase in oxidised biopterins (Fig. 4D). There was no significant difference in plasma nitrite/nitrate production between saline treated mice and LPS treated mice in either wild-type or Gch1/fl/Tie2cre mice (Fig. 4G). These data indicated that the dose of LPS used, although sufficient to cause alteration in biopterin and NOS biology does not cause an overwhelming NOS activation, as may be observed with higher doses of LPS [10].

3.5. Endothelial cell BH4 deficiency reduces LPS-induced vascular dysfunction in resistance mesenteric arteries

To investigate the relationships between blood pressure and changes in the resistance vasculature, mesenteric arteries from wild-type and Gch1/fl/Tie2cre mice were harvested from LPS or saline-treated animals.
24 h after injection. In wild-type mesenteric arteries, LPS administration significantly attenuated the contractile response to the α-adrenoceptor agonist phenylephrine (PE) (Fig. 5A; \( P < 0.05 \)). This blunting of the contractile response was prevented in the presence of L-NNAME (Fig. 5B), such that there was no longer a significant difference in vasoconstriction between saline-treated and LPS-treated wild-type mice. This indicates that increased NO-derived NO is responsible for the decreased vasoconstrictor response in mesenteric arteries from LPS-treated wild-type. Similar findings were also observed when thromboxane A2 agonist U46619 was used (Fig. 5C; \( P < 0.01 \)), suggesting that the blunted vasoconstrictor response was not due to specific alteration of receptor signalling on vascular smooth muscle cells. In contrast to these observations in wild-type mice, LPS treatment in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice resulted in no significant alteration in vasoconstrctor response to either PE or U46619 (Fig. 5A and B respectively). Furthermore, L-NNAME treatment had no effect on contractile response in LPS-treated \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice (Fig. 5B and D).

In saline treated mice, endothelium-dependent vasodilatation in response to acetylcholine was significantly impaired in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mesenteric arteries when compared with that in wild-type mesenteric arteries (\( P < 0.001 \)). Following LPS treatment, endothelium-dependent vasodilatation was significantly impaired in wild-type mesenteric arteries (\( P < 0.05 \)), but unaltered in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mesenteric arteries, such that endothelium-dependent vasodilatation was no longer different between LPS treated wild-type and LPS-treated \( \text{Gch1}^{+/+}\text{Tie2cre} \) mesenteric arteries (Fig. 5E). Furthermore, LPS treatment significantly reduced the potency of endothelium-independent vasodilatation to SNP in wild-type mesenteric arteries when compared to mesenteric arteries from saline treated wild-type mice (Fig. 5F; \( P < 0.05 \)). In contrast, LPS treatment has no significant effect on endothelium-independent vasodilatation to SNP in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mesenteric arteries. This finding indicates that endothelial cell BH4 regulates LPS-induced vascular dysfunction in resistance arteries.

3.6. Endothelial cell BH4 deficiency prevents LPS-induced aortic dysfunction ex vivo

To determine the effect of endothelial cell BH4 deficiency on vascular function in response to a higher dose of LPS and a clear induction of vascular iNOS expression, isolated mouse aortic rings from wild-type and \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without 1 \( \mu \text{g/ml} \) of LPS for 24 h. Following incubation, GTPCH protein expression, BH4 and total biopterin levels were significantly increased in both wild-type and \( \text{Gch1}^{+/+}\text{Tie2cre} \) aortas (Fig. 6A, B and F). The induction of this pathway was significantly greater in wild-type aortas, which again does not occur in \( \text{Gch1}^{+/+}\text{Tie2cre} \) aortas despite induction of iNOS and eNOS protein expression in both genotypes. The major implication of this finding is that vascular GTPCH and BH4 biosynthesis is alone sufficient to protect against LPS-induced vascular dysfunction and hypotension induced by the dose of LPS used here, indicating a novel role of endothelial cell \( \text{Gch1} \) and BH4-dependent NO regulation in the pathogenesis of LPS-induced vascular dysfunction and hypotension.

A large body of evidence has demonstrated that administration of bacterial LPS causes an increase in vascular \( \text{Gch1} \) mRNA, GTPCH protein expression and BH4 levels in a coordinated manner with iNOS mRNA such that vascular iNOS-derived NO is increased [3,21,26]. Consistent with this, we found that in vivo LPS treatment causes an increase in vascular GTPCH protein and BH4 levels in endothelial cell-rich tissues such as aortas, lungs and hearts from wild-type mice. We have previously reported that the majority of vascular GTPCH and BH4 biosynthesis (\( \sim 70\% \)) is contributed by the endothelium in healthy mice [7] and human [11]. Thus, the endothelium may be a principal site of BH4 synthesis following LPS treatment. Indeed, endothelial-denudation leads to a reduction of vascular BH4 levels in aortas from LPS treated wild-type but unaltered in LPS treated \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice, demonstrating involvement of endothelial cells in GTPCH and BH4 biosynthesis in LPS-induced endotoxaemia. However, as a significant induction of BH4 is still observed in \( \text{Gch1}^{+/+}\text{Tie2cre} \) aortic tissues, other cell types must also upregulate BH4 production.

When a higher dose of LPS was applied to aortic rings ex vivo, an increase in aortic iNOS protein in both wild-type and \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice was observed. Interestingly, aortic eNOS expression was also markedly increased in both genotypes following LPS ex vivo. This increased eNOS expression may act as a protective mechanism in endotoxaemia contributing to the maintenance of microcirculatory flow. However, as the ex vivo incubation system occurs in the absence of blood flow and the resulting sheer stress on the vessel wall care must be taken in extrapolating these results to the in vivo situation. However, increased eNOS expression has been documented in mesenteric arteries and skeletal muscle from an in vivo experimental model of LPS-induced endotoxaemia [1,6]. In contrast, ENOS expression is decreased in vascular tissues from experimental models of severe septic shock [5,12], indicating that vascular eNOS expression is dependent on the severity of disease induced by LPS. In the present study we found that the reduced vasoconstrictor response is reversed by L-NNAME in mesenteric arteries from wild-type mice following LPS in vivo, indicating that this is mediated by LPS-induced increases in tonic NO-induced NO. In contrast to wild-type mesenteric arteries, LPS treatment has no effect on vasoconstrictor responses in mesenteric arteries from \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice. Similar findings were also observed in conduit arteries (aortas) from \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice pre-incubated with LPS ex vivo.

Interestingly, endothelium-dependent and independent vasodilatations were impaired in mesenteric arteries from wild-type mice following LPS in vivo. This finding was consistent with previous reports, which had also described a decrease in sensitivity to NO following LPS treatment, and this was shown to be iNOS dependent in the mesentry [5,19]. In contrast, LPS had no significant effect on either endothelium-dependent or independent vasodilatation in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice following LPS in vivo, indicating that the inability to induce endothelial

4. Discussion

In this study, we have demonstrated the specific role of endothelial cell BH4-dependent NO regulation in the pathogenesis of LPS-induced vascular dysfunction and hypotension. The major findings of this study are as follows. First, LPS treatment results in a significant increase in vascular GTPCH and BH4 levels in wild-type mice, but the magnitude of this increase is attenuated in \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice, demonstrating a specific endothelial cell component of this response. Second, in vivo LPS treatment causes a reduction in vasoconstrictor responses and an impairment of endothelium-dependent and independent vasodilatation in mesenteric arteries from wild-type mice, which are preserved in mesenteric arteries from \( \text{Gch1}^{+/+}\text{Tie2cre} \) mice. Third, ex vivo LPS treatment causes a NO-mediated reduction in vasoconstrictor responses in wild-type aortas, which again does not occur in \( \text{Gch1}^{+/+}\text{Tie2cre} \) aortas despite induction of iNOS and ENOS protein expression in both genotypes. Fourth, the lack of endothelial cell BH4 results in an attenuation of LPS-induced hypotension. Together these findings demonstrate for the first time that deficiency in endothelial cell \( \text{Gch1} \) and thus BH4 biosynthesis is alone sufficient to protect against LPS-induced vascular dysfunction and hypotension induced by the dose of LPS used here, indicating a novel role of endothelial cell \( \text{Gch1} \) and BH4-dependent NO regulation in the pathogenesis of LPS-induced vascular dysfunction and hypotension.
We demonstrated for the first time that deficiency of BH4 in the endothelial cell alone is protective against LPS-induced hypotension. However, endotoxaemia and sepsis seen in...
critically ill patients and more severe animal models are typified by a more profound decrease in blood pressure that causes organ failure through underperfusion and death. Under these conditions iNOS is expressed widely both locally within other vessel wall cells such as smooth muscle cells, and in other non-vascular cells. In the data presented here the lack of endothelial cell Gch1 and reduced BH4 levels, whilst providing significant protection, is not sufficient to entirely prevent hypotension. The drop in blood pressure that is still observed in mice demonstrates that limiting BH4 synthesis in smooth muscle cells GTPCH is reported to cause allosteric negative feedback regulation in dysfunction and hypotension induced by LPS[16,23]. Consistent with this idea, GTPCH feedback regulatory protein (GFRP) binding to GTPCH is reported to cause allosteric negative feedback regulation in the presence of excess BH4 production. The GFRP over expressing mice demonstrate that limiting BH4 synthesis in smooth muscle cells is partially protected from hypotension in the caecal ligation and puncture (CLP) model of sepsis [28]. Interestingly, heart rate was significantly reduced in both wild-type and Gch1fl/Te2cre mice following LPS treatment, indicating LPS mediated physiological changes that are independent of blood pressure. This finding is consistent with previous reports both at low dose and high dose of LPS [25,27] where bradycardia following LPS has been reported to be associated with a down-regulation of β1-adrenoceptor level in the myocardium [27].

Although deficiency in endothelial cell Gch1 and BH4 protects against LPS-induced vascular dysfunction and hypotension in Gch1fl/Te2cre mice using this non-lethal LPS dosing regimen, it is unknown whether deficiency in endothelial cell Gch1 and BH4 biosynthesis is protective against endotoxaemia caused by LPS at higher doses or during septic shock in vivo. Investigation using vascular smooth muscle cell-specific Gch1 deletion (e.g. SM22-cre mice) mice or knock out of Gch1 in both endothelial cells and vascular smooth muscle cells may provide an insight into understanding the role of Gch1 and BH4-dependent NO regulation in different vessel wall cells in the pathophysiology of LPS-induced endotoxaemia and septic shock.

Systemic administration of non-selective NOS inhibitors Nω-methyl-l-arginine (L-NMMA) has been shown to reduce plasma nitrite and nitrate and increase systemic vascular resistance and blood pressure in humans with septic shock; it did not however improve mortality in patients with septic shock [2,13,18]. Similarly, inhibition of NOS has been shown to have inconsistent effect in experimental model of endotoxaemia and septic shock. These observations indicate that the role of NO in endotoxaemia and septic shock is complex. This is likely due to the opposing local effects in the microcirculation. Reduced local NO in organ microcirculation, due to NOS inhibitor treatment, may lead to microcirculation hypoperfusion and organ damage in the model of endotoxaemia and septic shock. In contrast, supplementation of BH4 has been shown to maintain microcirculation flow and perfusion and increase the rate of survival in ovine model of peritoneal sepsis [17]. Thus, achieving the right balance between reducing hypotension, whilst maintaining organ perfusion in microcirculation may have therapeutic potential in the treatment of septic patients and understanding the cell type and enzymatic source of the NO contributing to both pathologies may be key to achieving this.

5. Conclusions

We have demonstrated for the first time that deficiency in endothelial cell Gch1 and BH4 biosynthesis protects against LPS-induced vascular dysfunction and hypotension. These findings suggest that endothelial cell BH4-dependent iNOS regulation plays a critical role in the pathogenesis of this LPS-induced endotoxaemia. Thus, targeting endothelial cell Gch1 and BH4 biosynthesis may provide a novel therapeutic target for the treatment of circulatory collapse in patients with septic shock.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.vph.2015.08.009.

Disclosures

None.

Acknowledgements

S. Chuaiphichai and the work presented here are supported by the BHF Centre of Research Excellence [RE/13/1/30181], British Heart Foundation grants [RG/10/15/28578] and [RG/12/5/29576], Wellcome Trust Core grant [080532/Z/09/Z] and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre.

References


